Australian actor Richard Norton dies after injecting unapproved peptides at double dose

A documented death linked to unapproved peptide therapy has triggered regulatory scrutiny in Australia. The case establishes measurable risk: self-administered overdose of experimental compounds without robust safety data led to fatal anaphylaxis. The coroner's recommendation to reclassify peptides from schedule 4 (prescription-only) to schedule 10 (experimental/trials only) would restrict prescriber access and patient availability, affecting clinical practices, compounding pharmacies, and practitioners currently offering peptide therapy. The TGA review outcome will determine whether these compounds remain accessible through licensed prescribers or move under tighter experimental protocols.